Amblyopia (Lazy-eye) affects 3% of all population and puts the patients at risk for eventual vision loss.
Gold Standard treatment for lazy eye is placing a
patch over the strong eye – an old-fashioned solution which suffers from very low compliance.
With the CureSight™ binocular treatment, children develop stereoscopic vision, which is difficult to be achieved with the monocular nature of the traditional patching treatment.
Amblyopia (Lazy-eye) affects 3% of all population and puts the patients at risk for eventual vision loss. Gold Standard treatment for lazy eye is placing a patch over the strong eye – an old-fashioned solution which suffers from very low compliance With the CureSight™ binocular treatment, children develop stereoscopic vision, which is difficult to be achieved with the monocular nature of the traditional patching treatment.
Multicenter, randomized, controlled pivotal study of CureSight against the gold standard patching
Parents that are likely or very likely to choose the CureSight over patching
As objectively measured by CureSight’s eye tracking system
The CureSight was awarded the IRON A’ Design Award in 2021 – 2022 Medical Devices and Medical Equipment Design Category.
Visit the award page
CureSight has received a Gold Award the 24th annual Digital Health Awards® Spring 2022 program in the Telehealth / Remote Patient Monitoring category.
© 2022 NovaSight | All Rights Reserved | NS-00779R04
Disclaimer: Caution – EyeSwift® and CureSight™ are investigational devices, limited by Federal (Or United States) law to investigational use
This website uses cookies for functional, operational, analytical and advertising purposes. Please review our Privacy Policy for more information